Cargando…
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma
BACKGROUND: The majority of chordomas show activation of the platelet-derived growth factor receptor (PDGFR). Based on in vitro intertumoral variation in response to recombinant PDGF protein and PDGFR inhibition, and variable tumor response to imatinib, we hypothesized that chordomas resistant to PD...
Autores principales: | Lee, Dae-Hee, Zhang, Ying, Kassam, Amin B., Park, Myung-Jin, Gardner, Paul, Prevedello, Daniel, Henry, Stephanie, Horbinski, Craig, Beumer, Jan H., Tawbi, Hussein, Williams, Brian J., Shaffrey, Mark E., Egorin, Merrill J., Abounader, Roger, Park, Deric M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527706/ https://www.ncbi.nlm.nih.gov/pubmed/26247786 http://dx.doi.org/10.1371/journal.pone.0134426 |
Ejemplares similares
-
MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET
por: Zhang, Ying, et al.
Publicado: (2014) -
Identification of repurposed small molecule drugs for chordoma therapy
por: Xia, Menghang, et al.
Publicado: (2013) -
Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas
por: Seeling, Carolin, et al.
Publicado: (2023) -
Craniovertebral junction chordomas: Case series and strategies to overcome the surgical challenge
por: Baldassarre, Bianca Maria, et al.
Publicado: (2021) -
AKT1-CREB stimulation of PDGFRα expression is pivotal for PTEN deficient tumor development
por: Wan, Xiaofeng, et al.
Publicado: (2021)